The translation inhibitor silvestrol exhibits direct anti-tumor activity while preserving innate and adaptive immunity against EBV-driven lymphoproliferative disease

Treatment options for patients with Epstein-Barr Virus-driven lymphoproliferative diseases (EBV-LPD) are limited. Chemo-immunotherapeutic approaches often lead to immune suppression, risk of lethal infection and EBV reactivation, thus it is essential to identify agents that can deliver direct anti-t...

Descripción completa

Detalles Bibliográficos
Autores principales: Patton, John T., Lustberg, Mark E., Lozanski, Gerard, Garman, Sabrina L., Towns, William H., Drohan, Callie M., Lehman, Amy, Zhang, Xiaoli, Bolon, Brad, Pan, Li, Kinghorn, A. Douglas, Grever, Michael R., Lucas, David M., Baiocchi, Robert A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2014
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4413611/
https://www.ncbi.nlm.nih.gov/pubmed/25393910

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4413611/
https://www.ncbi.nlm.nih.gov/pubmed/25393910

Ejemplares similares